Quantcast

Latest Diabetic retinopathy Stories

2014-09-16 08:29:26

Regeneron plans to submit sBLA for this indication by year end TARRYTOWN, N.Y., Sept. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted EYLEA(®) (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The designation is based on positive results in two Phase 3 trials (VIVID-DME and VISTA-DME), in which...

2014-09-04 04:21:42

TARRYTOWN, N.Y., Sept. 4, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has submitted a marketing authorization application for EYLEA(®) (aflibercept) Injection for macular edema following branch retinal vein occlusion (BRVO) to the Japanese Ministry of Health, Labour and Welfare (MHLW). EYLEA has already been approved in Japan for the treatment of patients with neovascular (wet)...

2014-09-03 23:08:57

Developed to improve the reading experience for those affected by low vision, the unique design of the ClearView C provides more working space and helps users to read or view any material, enjoy hobbies or write without being restricted in movement. VISTA, CA (PRWEB) September 03, 2014 Optelec, U.S. introduces the new ClearView C desktop video magnifier. Worldwide, there are around 160 million people who are visually impaired. As people get older, sight problems become more common. People...

2014-09-03 20:23:43

MarketOptimizer.org adds new report "Epicast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023" to its store. DALLAS, Sept. 3, 2014 /PRNewswire-iReach/ -- Macular edema (ME) occurs due to the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. In ME, fluid and protein deposits collect on or under the macula of the eye, due to a breakdown in the blood-retinal barrier. The occurrence of ME is highly frequent in...

2014-08-26 16:28:14

LONDON, Aug. 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Diabetic Retinopathy Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/diabetic_retinopathy_global_clinical_trials_review.htmlDiabetic Retinopathy Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Diabetic Retinopathy Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Retinopathy...

2014-08-20 08:27:26

SOUTHAMPTON, England, August 20, 2014 /PRNewswire/ -- Phase I Trial of Plasma Kallikrein Inhibitor to be Conducted in the US KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. The study's Principal Investigator is Dr. Jennifer K Sun of the Beetham Eye Institute, Joslin...

2014-08-11 04:21:54

TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema (DME). Bayer Healthcare plans to launch EYLEA in DME in the EU this quarter. "DME is the leading cause of vision loss in working-age adults in much of the developed world, and we believe EYLEA will be an important new treatment...

2014-08-05 12:25:50

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:U.S. Market and Survey for Retinopathy Screening Deviceshttp://www.reportbuyer.com/pharma_healthcare/diseases/u_s_market_survey_retinopathy_screening_devices.htmlAbstract:The market for diabetic retinopathy screening devices is in its infancy. Growth is expected under all forecast scenarios; however, the rate of growth will be determined by pricing and reimbursement. Several different...

2014-07-29 20:23:16

DME is the third approved indication for EYLEA in the U.S. TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA(®) (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). The recommended dosage of EYLEA in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections. Although EYLEA may be dosed as...

2014-07-18 08:23:16

TARRYTOWN, N.Y., July 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the Phase 3 VIVID-DME trial of EYLEA(®) (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related